SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal Holdings is trending following reports of potential acquisition interest from Stripe, sparking widespread community discussion about a possible bidding war for the deeply undervalued payments giant. Investors are actively debating various buyout scenarios, recognizing PayPal's extensive user base and robust cash generation capabilities.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending into its anticipated earnings report, with the community discussing expectations for an 18th consecutive beat and raise, fueled by its AI-powered platform and proprietary data moat, even as the stock navigates broader software sector volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as Warner Bros. Discovery evaluates a revised, higher bid from Paramount Skydance, driving fervent community discussion on whether Netflix should match the offer or walk away, with many believing the latter would lead to a significant stock rally by avoiding the acquisition.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is a top trending stock as its latest earnings results and outlook have fueled significant investor frustration and concerns over continued share dilution needed to fund upcoming vehicle platforms. The community is actively debating the company's persistent cash burn and leadership uncertainty, leading to a largely pessimistic sentiment for the luxury EV manufacturer amidst a challenging sector.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday Inc is trending as its latest earnings, which beat estimates, were met with a significant sell-off after the company issued a lower-than-anticipated subscription revenue forecast, intensifying community debate over AI's potential disruption to the software sector and future growth.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending following its recent financial results that surpassed revenue expectations and offered optimistic guidance, fueling discussions around its advanced GaN and SiC power platforms crucial for next-gen AI data centers. The community is actively weighing the immense potential of its technology and perceived positioning within the NVIDIA ecosystem against persistent concerns regarding a lack of definitive, revenue-generating contracts.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is generating significant conversation following a strong Q4 earnings report and ambitious long-term revenue targets, with the community enthusiastically discussing its growth and potential impact from increasing body camera mandates, even as some debate its high valuation and recent market performance.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following robust preliminary Q4 and full-year 2025 results showcasing substantial revenue growth and record total contract value, which is fueling bullish analyst upgrades and reported institutional buying. Despite mixed market reactions and discussions around profitability, many in the community are actively buying dips amidst high short interest in the AI-driven healthcare platform.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following its Q4 earnings report, which highlighted robust revenue and expansion plans, sparking community debate over profitability challenges and whether its high valuation is justified amidst mixed performance metrics.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is trending as its board evaluates a revised offer from Paramount Skydance, which could be deemed a superior proposal, intensifying the bidding war and prompting community debate on whether Netflix will match or if regulatory hurdles will impact the high-stakes media acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6% - Time to Sell?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 7.6% - Time to Sell...

Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 25.9% in the 3rd quarter, according to its most recent filing with the Securities and...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat...

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know 

Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3% - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.3% - Here's What Happened...

Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains

Corvus Pharmaceuticals (NASDAQ:CRVS) presented new Phase I results for oral soquelitinib in moderate-to-severe atopic dermatitis (AD), highlighting updated efficacy, durability, and safety findings...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's Why...

<ul class="summary-bullets"><li>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.</li><li>This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.</li><li>The company expects to close the offering on or about Jan. 23, 2026.</li></ul>Corvus Pharmaceuticals Inc. (CRVS) shares were up&nbsp;more than 7% in&nbsp;Thursday’s&nbsp;pre-market trade after the company announced an upsized public stock offering.Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15. The company stated that underwriters have a 30-day option to purchase an additional 1.18 million shares.The company expects to close the offering on or about Jan. 23, 2026.<h2 class="st-heading-2">Use Of Net Proceeds</h2>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials, sales and marketing and administrative expenses.<h2 class="st-heading-2">Positive Atopic Dermatitis Trial Results</h2>Corvus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-crvs-stock-rising-today/cmUuNzGR4aM">announced</a> on Tuesday that cohort 4 of its placebo-controlled trial showed favorable safety and efficacy results, consistent with those of the previous three cohorts.Corvus stated that all patients in cohort 4 had completed the 56-day treatment course and had similar baseline characteristics to those in the previous cohort. However, they had a higher mean baseline EASI (Eczema Area and Severity Index) score compared to patients in cohorts 1 and 2.“The results from cohort 4 increase our confidence that soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis,” said Corvus CEO Richard A. Miller.<h2 class="st-heading-2">Retail Sounds Optimistic</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CRVS">Corvus Pharmaceuticals</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘extremely high’ levels.One bullish user on the platform pointed to inbound partnerships and institutional buying, stating that the stock could “double again soon.”<stembedurl>https://stocktwits.com/fubar444/message/642514507</stembedurl>Another user stated that the CRVS stock will “rocket” once the offering closes.<stembedurl>https://stocktwits.com/SleepyDon/message/642502522</stembedurl><a href="https://stocktwits.com/symbol/CRVS">CRVS stock</a> is up 188% year-to-date and 324% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-indian-antitrust-regulator-prevent-global-financial-records-38-billion-fine/cmUzwavR4QZ">Apple Seeks To Prevent India’s Antitrust Regulator From Accessing Global Financial Records As It Fears A $38 Billion Fine: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corvus Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Equity

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc